Archives: Agenda
NMPA SPOTLIGHT The 2-3 x Speed Advantage: Inside China’s Integrated Discovery-to-IND Machine 2-3倍速优势:解码中国一体化发现至IND申报加速引擎
- Strategic Meaning of NMPA 30-days Pathway
- How to Leverage Platform & Technology Stack
- Empowered by Capital & Talent Alignment
- Lessons for Accelerating Worldwide Pipelines
- NMPA 30天临床默示许可的战略内涵
- 如何最大化平台与技术栈的杠杆效应
- 资本与人才的同频共振
- 全球管线的中国加速启示
KEYNOTE PANEL: The Patient Enrollment Revolution: Global Lessons from China’s Clinical Trial Efficiency 主旨圆桌:患者入组革命——中国临床试验效率的全球启示
Patient enrollment remains one of the most critical bottlenecks in global drug development, often delaying timelines, increasing costs, and limiting patient access to innovative therapies. Against this backdrop, China has emerged not merely as a region of vast patient numbers, but as a laboratory for systemic innovation in clinical trial execution.
|
患者入组仍然是全球药物研发中最关键的瓶颈之一,常常导致周期延误、成本攀升,并限制患者对创新疗法的可及性。在这一背景下,中国不仅凭借庞大的患者基数脱颖而出,更成为临床试验执行层面系统性创新的试验田。
|
Session 2: Future Trends: Preparing for 2027
Session 1: Navigating Tech Buying Decisions
Coffee Morning Session: Women in Hospitality
Moderator: Rachelle Peterson, Founder, Rebound & Rise